Perspectives in HIV protease inhibitors

Advances in Experimental Medicine and Biology

Volumn 394, Issue , 1996, Pages 319-325

  Leonard, John M ^b  

^a ABBOTT LABORATORIES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

A 77003; A 80987; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; BINDING SITE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ACTIVITY; DRUG BIOAVAILABILITY; ENZYME ACTIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; PROTEINASE INHIBITION; STRUCTURE ACTIVITY RELATION; VIRUS ISOLATION;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0029865526     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4757-9209-6_29     Document Type: Conference Paper

References (15)

1. Kohl NE, Emini EA, Schleif WA, et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 1988;85:4686-90.
2. Norbeck DW. Recent advances in anti-retroviral chemotherapy for AIDS. Annu Rep Med Chem 1989 1989;25:149-58.
3. Meek TD, Dreyer GB. HIV-1 protease as a potential target for anti-AIDS therapy. Ann NY Acad Sci 1990;616:41-53.
4. Peng C, Ho BK, Chang TW, Chang NT. Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J Virol 1989;63:2550-6.
5. Le Grice SFJ, Mills J, Mous J. Active site mutagenesis of the AIDS virus protease and its alleviation by trans complementation. EMBO J 1988;7:2547-53.
6. Vacca JP, Guare JP, deSolms SJ, et al. L-687,908, a potent hydroxyethylene-containing HIV protease inhibitor. J Med Chem 1991;34:1225-8.
7. 2 symmetric inhibitor complexed to HIV-1 protease. Science 1990;249:527-33.
8. Rosenberg SH, Kleinert HD, Stein HH, et al. Design of a well-absorbed renin inhibitor. J Med Chem 1991;34:469-71.
9. 2-symmetry based HIV protease inhibitor. Antimicrob Agents Chemother 1995;39:1559-1564.
10. Data on file, Abbott Laboratories.
11. Kempf DJ, Marsh KC, Denissen JF, et al. ritonavir is a potent inhibitor of human immunodeficiency virus protease with high oral bioavailability.
12. Kageyama S, Anderson BD, Hoesterey BL, Hayashi H, Kiso Y, Flora KP and Mitsuya H. Antimicrob Agents Chemother 1994;38:1107-1111.
13. Personal communication, G. Drusano.
14. Markowitz M, Mo H, Kempf DJ, et al. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ritonavir, a novel protease inhibitor. J Virol 1995;69:701-6.
15. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM and Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.